<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6518">
  <stage>Registered</stage>
  <submitdate>23/05/2017</submitdate>
  <approvaldate>23/05/2017</approvaldate>
  <nctid>NCT03171155</nctid>
  <trial_identification>
    <studytitle>Clinical Study of the Medeon Biodesign XPro</studytitle>
    <scientifictitle>Prospective, Multi-Center, Single Arm Study of the Medeon Biodesign XPro Suture-Mediated Vascular Closure Device System</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CIP-LHC03</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Percutaneous Closure of Arteriotomy in Common Femoral Artery</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - XPro System

Experimental: XPro System - Implantation of XPro System during percutaneous vascular closure


Treatment: devices: XPro System
Implantation of the XPro System

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to Hemostasis - Time to hemostasis absent of any access-site-related adjunctive surgical or endovascular procedures.</outcome>
      <timepoint>15 minutes</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Freedom from major VARC-2 events - Freedom from major VARC-2 events within 30 days of the procedure.</outcome>
      <timepoint>Up to 30 days of procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from minor VARC-2 events - Freedom from minor VARC-2 events up to 30 days of the procedure.</outcome>
      <timepoint>Up to 30 days of procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Successful hemostasis with the XPro System - Without the need for any access-site-related adjunctive surgical or endovascular procedures and freedom from major VARC-2 events.</outcome>
      <timepoint>at 48 hours or at discharge from hospital, whichever comes first; and up to 30 days post-procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from access-site infection - Freedom from access-site infection requiring IV or IM antibiotics, or extended hospitalization or re-hospitalization.</outcome>
      <timepoint>Up to 30 days of procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient is &gt; 18 years old

          -  Patient is scheduled for percutaneous BAV, TAVR/TAVI, EVAR, or TEVAR involving access
             through the femoral artery using an 8-18 Fr introducer sheath

          -  Patient is able to undergo emergent vascular surgery if a complication related to the
             vascular closure necessitates such surgery

          -  Patient, or authorized representative, signs a written Informed Consent form to
             participate in the study, prior to any study mandated procedures

          -  Patient is willing and able to complete follow-up</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior intra-aortic balloon pump at access site

          -  Patients with severe claudication, iliac or femoral artery diameter stenosis greater
             than 50%

          -  Common femoral artery lumen diameter is &lt; 6 mm

          -  Prior target artery closure with any closure device &lt; 90 days, or closure with manual
             compression = 30 days prior to index procedure

          -  Prior vascular surgery, vascular graft, or stent in region of access site

          -  Patients receiving glycoprotein IIb/IIIa inhibitors before, during, or after the
             catheterization procedure

          -  Patients with significant anemia ((Hgb &lt; 10 g/dL, Hct &lt; 30%)

          -  Patient with known bleeding disorder including thrombocytopenia (platelet count &lt;
             100,000), thrombasthenia, hemophilia or Von Willebrand's disease

          -  Patients with renal insufficiency (serum creatinine level &gt; 221Âµmol/L) or renal
             transplant

          -  Known allergy to contrast reagent

          -  Inability to tolerate aspirin and/or other anticoagulation treatment

          -  Planned anticoagulation therapy post-procedure such that ACT is expected to be
             elevated above 350 seconds for more than 24 hours after the procedure

          -  Connective tissue disease (e.g., Marfan's Syndrome)

          -  Thrombolytics (e.g. t-PA, streptokinase, urokinase), Angiomax (bivalirudin) or other
             thrombin-specific anticoagulants = 24 hours prior to the procedure

          -  Recent (within 8 weeks) cerebrovascular accident or Q-wave myocardial infarction

          -  Patients who are morbidly obese BMI &gt; 40 kg/m2

          -  Planned major intervention or surgery within 30 days following the interventional
             procedure

          -  Patients who are unable to ambulate at baseline

          -  Currently participating in a clinical study of an investigational device or drug that
             has not completed study endpoint

          -  Known allergy to any device component

          -  Patient is known or suspected to be pregnant or lactating

          -  Life expectancy &lt; 1 year as judged by the investigator

          -  Patient has other medical, social or psychological problem that in the opinion of the
             investigator precludes them from participating Intra-Procedure

          -  Access site above the most inferior border of the inferior epigastric artery (IEA)
             and/or above the inguinal ligament based upon bony landmarks

          -  Access site in the profunda femoris or superficial femoral arteries, or the
             bifurcation of these vessels

          -  Ipsilateral femoral venous sheath during the catheterization procedure

          -  Common femoral artery calcium, which is fluoroscopically visible

          -  Patients where there is difficulty inserting the introducer sheath or greater than 2
             ipsilateral arterial punctures at the start of the catheterization procedure

          -  Difficulty in obtaining vascular access resulting in multiple arterial punctures
             and/or posterior arterial puncture

          -  Evidence of a pre-existing hematoma, arteriovenous fistula, or pseudoaneurysm at the
             access site

          -  Patients with intra-procedural bleeding around access site

          -  Evidence of active systemic or local groin infection

          -  Patients receiving glycoprotein IIb/IIIa inhibitors during, or after the
             catheterization procedure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/05/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medeon Biodesign, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To access the safety and performance of the XPro System to facilitate hemostasis in patients
      undergoing percutaneous endovascular procedures utilizing 8-18 Fr introducer sheath via the
      common femoral.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03171155</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amy Forro, BS</name>
      <address />
      <phone>508-254-1005</phone>
      <fax />
      <email>aforro@linceconsulting.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>